The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1712
ISSUE1712
September 30, 2024
Drugs for Plaque Psoriasis
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Plaque Psoriasis
September 30, 2024 (Issue: 1712)
Mild to moderate plaque psoriasis can be treated
with topical drugs and phototherapy. Patients
with moderate to severe disease generally require
systemic therapy. Guidelines for the treatment of
psoriasis with topical therapy, phototherapy,...more
- CA Elmets et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 2021; 84:432. doi:10.1016/j.jaad.2020.07.087
- CA Elmets et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol 2019; 81:775. doi:10.1016/j.jaad.2019.04.042
- A Menter et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020; 82:1445. doi:10.1016/j.jaad.2020.02.044
- A Menter et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019; 80:1029. doi:10.1016/j.jaad.2018.11.057
- Calcipotriene/betamethasone foam (Enstilar) for psoriasis. Med Lett Drugs Ther 2016; 58:48.
- Calcitriol (Vectical) for mild to moderate plaque psoriasis. Med Lett Drugs Ther 2009; 51:70.
- LA Mohney et al. Tazarotene 0.045% lotion: a novel retinoid formulation. Ann Pharmacother 2022; 56:1174. doi:10.1177/10600280211072155
- Tapinarof cream (Vtama) for psoriasis. Med Lett Drugs Ther 2022; 64:122.
- MG Lebwohl et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med 2021; 385:2219. doi:10.1056/nejmoa2103629
- B Strober et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial J Am Acad Dermatol 2022; 87:800. doi:10.1016/j.jaad.2022.06.1171
- Topical roflumilast (Zoryve) for plaque psoriasis. Med Lett Drugs Ther 2023; 65:10.
- MG Lebwohl et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA 2022; 328:1073. doi:10.1001/jama.2022.15632
- D Amiri et al. Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review. Acta Derm Venereol 2023; 103:adv00890. doi:10.2340/actadv.v103.6525
- NW Andersson et al. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. JAMA Dermatol 2021; 157:788. doi:10.1001/jamadermatol.2021.1090
- DC Butler et al. Safety of dermatologic medications in pregnancy and lactation: part II. lactation. J Am Acad Dermatol 2014; 70:417.e1. doi:10.1016/j.jaad.2013.09.009
- C Ferreira et al. Management of psoriasis in pregnancy – a review of evidence to date. Drugs Context 2020; 9:2019. doi:10.7573/dic.2019-11-6
- M Abrouk et al. Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability. Psoriasis (Auckl) 2016; 6:165. doi:10.2147/ptt.s105047
- IH Kim et al. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol 2012; 13:365. doi:10.2165/11633110-000000000-00000
- AB Gottlieb et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol 2018; 79:302. doi:10.1016/j.jaad.2018.04.012
- RE Kalb et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 2015; 151:961. doi:10.1001/jamadermatol.2015.0718
- F Valenzuela and R Flores. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics (Sao Paulo) 2021; 76:e3015. doi:10.6061/clinics/2021/e3015
- KA Papp et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 2). Lancet 2008; 371:1675. doi:10.1016/s0140-6736(08)60726-6
- Secukinumab (Cosentyx) for psoriasis. Med Lett Drugs Ther 2015; 57:45.
- Ixekizumab (Taltz) – a second IL-17A inhibitor for psoriasis. Med Lett Drugs Ther 2016; 58:59.
- Brodalumab (Siliq) – another IL-17A antagonist for psoriasis. Med Lett Drugs Ther 2017; 59:118.
- M Lebwohl et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318. doi:10.1056/nejmoa1503824
- J Bagel et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb) 2018; 8:571. doi:10.1007/s13555-018-0265-y
- K Reich et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol 2017; 177:1014. doi:10.1111/bjd.15666
- RG Langley et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326. doi:10.1056/nejmoa1314258
- CEM Griffiths et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541. doi:10.1016/s0140-6736(15)60125-8
- A Chiricozzi et al. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf 2016; 15:1653. doi:10.1080/147403 38.2016.1228872
- Bimekizumab (Bimzelx) for psoriasis. Med Lett Drugs Ther 2024; 66:11.
- K Reich et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 2021; 397:487. doi:10.1016/s0140-6736(21)00125-2
- RB Warren et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med 2021; 385:130. doi:10.1056/nejmoa2102388
- KB Gordon et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 2021; 397:475. doi:10.1016/s0140-6736(21)00126-4
- Guselkumab (Tremfya) for psoriasis. Med Lett Drugs Ther 2017; 59:179.
- Risankizumab (Skyrizi) for plaque psoriasis. Med Lett Drugs Ther 2019; 61:81.
- Tildrakizumab (Ilumya) – another IL-23 antagonist for psoriasis. Med Lett Drugs Ther 2019; 61:4.
- A Blauvelt et al. Efficacy and safety of guselkumab, an antiinterleukin- 23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76:405. doi:10.1016/j.jaad.2016.11.041
- K Reich et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomized, controlled trial. Lancet 2019; 394:831. doi:10.1016/s0140-6736(19)31773-8
- KB Gordon et al. Efficacy and safety of risankizumab in moderateto- severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392:650. doi:10.1016/s0140-6736(18)31713-6
- K Reich et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 2019; 394:576. doi:10.1016/s0140-6736(19)30952-3
- K Reich et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390:276. doi:10.1016/s0140-6736(17)31279-5
- ACOG. Committee Opinion No. 776 summary: immune modulating therapies in pregnancy and lactation. Obstet Gynecol 2019; 133:846. doi:10.1097/aog.0000000000003177
- RB Warren et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:528. doi:10.1016/s0140-6736(16)32127-4
- VMR Heydendael et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658. doi:10.1056/nejmoa021359
- I Flytström et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158;116. doi:10.1111/j.1365-2133.2007.08284.x
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- K Reich et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol 2018; 32:397. doi:10.1111/jdv.14738
- Deucravacitinib (Sotyktu) for plaque psoriasis. Med Lett Drugs Ther 2023; 65:29.
- AW Armstrong et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 2023; 88:29. doi:10.1016/j.jaad.2022.07.002
- B Strober et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 2023; 88:40. doi:10.1016/j.jaad.2022.08.061
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Plaque Psoriasis
Article code: 1712a
Article code: 1712a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.